Cargando…
Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study
INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination has been effective in protecting against severe COVID-19 infections and related mortality. It is recommended for all individuals including patients with inflammatory bowel disease (IBD). However, safety data are l...
Autores principales: | Shehab, Mohammad, Alrashed, Fatema, Abdullah, Israa, Alfadhli, Ahmad, Ali, Hamad, Abu-Farha, Mohamed, Channanath, Arshad Mohamed, Abubaker, Jehad Ahmed, Al-Mulla, Fahd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215310/ https://www.ncbi.nlm.nih.gov/pubmed/35755075 http://dx.doi.org/10.3389/fmed.2022.881027 |
Ejemplares similares
-
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Shehab, Mohammad, et al.
Publicado: (2021) -
Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
por: Shehab, Mohammad, et al.
Publicado: (2021) -
Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study
por: Shehab, Mohammad, et al.
Publicado: (2022) -
Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin
por: Hasan, Amal, et al.
Publicado: (2022) -
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
por: Ali, Hamad, et al.
Publicado: (2021)